SG11201900665VA - Cannabis composition - Google Patents
Cannabis compositionInfo
- Publication number
- SG11201900665VA SG11201900665VA SG11201900665VA SG11201900665VA SG11201900665VA SG 11201900665V A SG11201900665V A SG 11201900665VA SG 11201900665V A SG11201900665V A SG 11201900665VA SG 11201900665V A SG11201900665V A SG 11201900665VA SG 11201900665V A SG11201900665V A SG 11201900665VA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- bay
- western australia
- perth
- pct
- Prior art date
Links
- 241000218236 Cannabis Species 0.000 title abstract 4
- 239000000203 mixture Substances 0.000 title abstract 2
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- XMGQYMWWDOXHJM-UHFFFAOYSA-N limonene Chemical compound CC(=C)C1CCC(C)=CC1 XMGQYMWWDOXHJM-UHFFFAOYSA-N 0.000 abstract 2
- 208000019116 sleep disease Diseases 0.000 abstract 2
- 208000020685 sleep-wake disease Diseases 0.000 abstract 2
- 150000003505 terpenes Chemical class 0.000 abstract 2
- 235000007586 terpenes Nutrition 0.000 abstract 2
- 239000002671 adjuvant Substances 0.000 abstract 1
- 239000003085 diluting agent Substances 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 239000003937 drug carrier Substances 0.000 abstract 1
- 235000001510 limonene Nutrition 0.000 abstract 1
- 229940087305 limonene Drugs 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 1
- 102220240796 rs553605556 Human genes 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/05—Phenols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/01—Hydrocarbons
- A61K31/015—Hydrocarbons carbocyclic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Anesthesiology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
WO 18/0 23 163 Al (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 08 February 2018 (08.02.2018) WIP0 I PCT omit VIII °nolo III mill VIII omioliono oimIE (10) International Publication Number WO 2018/023163 Al (51) International Patent Classification: A61K 31/352 (2006.01) A61K 36/00 (2006.01) A61K 31/05 (2006.01) A61P 25/20 (2006.01) (21) International Application Number: PCT/AU2017/050814 (22) International Filing Date: 03 August 2017 (03.08.2017) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/370,304 03 August 2016 (03.08.2016) US (71) Applicant: ZELDA THERAPEUTICS OPERATIONS PTY LTD [AU/AU]; Level 6, 105 St Georges Terrace, Perth, Western Australia 6000 (AU). (72) Inventors: KARELIS, Harry; Level 6, 105 St Georges Terrace, Perth, Western Australia 6000 (AU). GORDON, Mara; 3901 Bay Hill Rd, Bodega Bay, California 94923 (US). SMITH, Stewart; 3901 Bay Hill Rd, Bodega Bay, California 94923 (US). WASHER, Stewart; 6 Pemberton Close, Stirling, Western Australia 6021 (AU). Published: — with international search report (Art. 21(3)) (74) Agent: GRIFFITH HACK; Level 22, Allendale Square, 77 St Georges Terrace, Perth, Western Australia 6000 (AU). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). (54) Title: CANNABIS COMPOSITION (57) : The present invention relates to a method for treating a sleep disorder. Preferably, the invention relates to a method for treating a sleep disorder comprising the step of administering a pharmaceutical composition comprising a Cannabis extract and optionally one or more pharmaceutically acceptable carriers, diluents, adjuvants, excipients or any combination thereof, the Cannabis extract comprising a terpene fraction comprising limonene in an amount of at least about 5.4% by weight of the terpene fraction.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662370304P | 2016-08-03 | 2016-08-03 | |
| PCT/AU2017/050814 WO2018023163A1 (en) | 2016-08-03 | 2017-08-03 | Cannabis composition |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201900665VA true SG11201900665VA (en) | 2019-02-27 |
Family
ID=61072172
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201900665VA SG11201900665VA (en) | 2016-08-03 | 2017-08-03 | Cannabis composition |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US11779562B2 (en) |
| EP (1) | EP3493798A4 (en) |
| JP (1) | JP2019523283A (en) |
| KR (2) | KR20210013645A (en) |
| CN (1) | CN109843287A (en) |
| AU (4) | AU2017307643B2 (en) |
| BR (1) | BR112019001852A2 (en) |
| CA (1) | CA3031810A1 (en) |
| CL (1) | CL2019000270A1 (en) |
| CO (1) | CO2019001044A2 (en) |
| IL (2) | IL264461B2 (en) |
| MX (1) | MX2019001285A (en) |
| PE (1) | PE20200726A1 (en) |
| SG (1) | SG11201900665VA (en) |
| WO (1) | WO2018023163A1 (en) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG11201900501RA (en) | 2016-08-03 | 2019-02-27 | Zelda Therapeutics Operations Pty Ltd | Cannabis composition |
| US10239808B1 (en) | 2016-12-07 | 2019-03-26 | Canopy Holdings, LLC | Cannabis extracts |
| WO2018183115A1 (en) * | 2017-03-30 | 2018-10-04 | Ojai Energetics Pbc | Methods and compositions for enhancing health |
| AU2018100837B4 (en) * | 2017-06-19 | 2019-02-21 | Zelira Therapeutics Operations Pty Ltd | Sleep Disorder Compositions and Treatments Thereof |
| WO2019152736A1 (en) | 2018-01-31 | 2019-08-08 | Canopy Holdings, LLC | Hemp powder |
| WO2019173242A1 (en) * | 2018-03-04 | 2019-09-12 | Cmg Partners, Inc. | Enhanced smokable cannabis-based therapeutic product for treatment of sleep disorders and chronic pain and method for making same |
| WO2019241804A1 (en) * | 2018-06-15 | 2019-12-19 | California Cannabinoids | Compositions and methods for treatment of narcolepsy and related disorders |
| WO2020077153A1 (en) | 2018-10-10 | 2020-04-16 | Canopy Holdings, LLC | Synthesis of cannabigerol |
| US20220160648A1 (en) * | 2019-02-13 | 2022-05-26 | Inspired Health Products, LLC | Composition Comprising Hydrolyzed Collagen and Cannabidiol and Use Thereof |
| US11554098B2 (en) | 2019-05-03 | 2023-01-17 | HFL Partners, LLC | Compositions comprising molecularly separated cannabinoids and terpene blends and methods of producing |
| US11000818B1 (en) * | 2019-12-27 | 2021-05-11 | Cresco Labs Llc | Post processing method for cannabis oil |
| US20230000935A1 (en) * | 2021-07-03 | 2023-01-05 | Joseph Anthony Bidwell | Extract Infused Cannabis Flower, Natural preservation of Cannabis Flower and the method therefor |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2400320B (en) | 2001-05-04 | 2005-06-08 | Gw Pharma Ltd | Cannabinoid-rich extracts |
| JP4411117B2 (en) * | 2004-03-25 | 2010-02-10 | エスエス製薬株式会社 | Sleep improvement pharmaceutical composition |
| GB2418612A (en) | 2004-10-01 | 2006-04-05 | Gw Pharma Ltd | Inhibition of tumour cell migration with cannabinoids |
| JP2007246428A (en) * | 2006-03-15 | 2007-09-27 | Nature Technology Inc | Percutaneous absorption type antihypnotic composition containing plant essential oil component as active ingredient, percutaneous absorption type antihypnotic pharmaceutical formulation and method for producing the composition and formulation |
| GB2478595B (en) * | 2010-03-12 | 2018-04-04 | Gw Pharma Ltd | Phytocannabinoids in the treatment of glioma |
| TWI583374B (en) | 2010-03-30 | 2017-05-21 | Ｇｗ伐瑪有限公司 | Use of the phytocannabinoid cannabidivarin (cbdv) in the treatment of epilepsy |
| KR20110120153A (en) * | 2010-04-28 | 2011-11-03 | 고려대학교 산학협력단 | Adenosine a2a receptor agonist comprising limonene |
| GB2514054A (en) | 2011-09-29 | 2014-11-12 | Gw Pharma Ltd | A pharmaceutical composition comprising the phytocannabinoids cannabidivarin (CBDV) and cannabidiol (CBD) |
| GB2496688B (en) | 2011-11-21 | 2016-06-29 | Gw Pharma Ltd | Tetrahydrocannabivarin for use in the treatment of intestinal inflammatory diseases |
| EP2844243B8 (en) | 2012-05-03 | 2019-12-18 | Echo Pharmaceuticals B.V. | Method for preparing a cannabis plant isolate comprising delta-9-tetrahydrocannabinol |
| EP2934512B1 (en) | 2012-12-18 | 2021-11-24 | Kotzker Consulting LLC | Use of cannabinoids and terpenes for treatment of organophosphate and carbamate toxicity |
| EP4137142A1 (en) | 2013-03-14 | 2023-02-22 | Purple Mundo, Inc. | Bioactive concentrates and uses thereof |
| MX2015013202A (en) * | 2013-03-15 | 2016-04-07 | Biotech Inst Llc | Breeding, production, processing and use of specialty cannabis. |
| US10265292B2 (en) | 2013-09-18 | 2019-04-23 | The Werc Shop, LLC | Terpene-based compositions, processes methodologies |
| ES2739292T3 (en) * | 2013-10-29 | 2020-01-30 | Biotech Inst Llc | Cultivation, production, processing and use of specialty cannabis |
| EP3062774A2 (en) | 2013-10-31 | 2016-09-07 | Full Spectrum Laboratories, Ltd. | Terpene and cannabinoid formulations |
| CA2952934A1 (en) * | 2014-06-26 | 2015-12-30 | Island Breeze Systems Ca, Llc | Mdi related products and methods of use |
| AU2015279612A1 (en) | 2014-06-27 | 2017-02-02 | Kenton L. Crowley | Buccal and sublingual cannabinoid formulations and method of making the same |
| CA2996626A1 (en) * | 2014-08-25 | 2016-03-03 | Janing Holding Aps | Device with compositions for delivery to the lungs, the oral mucosa and the brain |
| MX2017005277A (en) * | 2014-10-21 | 2018-01-11 | United Cannabis Corp | Cannabis extracts and methods of preparing and using same. |
| EA201791299A1 (en) | 2014-12-12 | 2017-12-29 | ОХАЙ ЭНЕРДЖЕТИКС ПиБиСи | MICROINCAPSULATED COMPOSITIONS OF CANNABINOIDS |
| MX2017009846A (en) | 2015-01-31 | 2018-04-11 | Constance Therapeutics Inc | Methods for preparation of cannabis oil extracts and compositions. |
| CA2977802A1 (en) | 2015-02-27 | 2016-09-01 | Ebbu, LLC | Compositions comprising combinations of purified cannabinoids, with at least one flavonoid, terpene, or mineral |
| JP2019523282A (en) | 2016-08-03 | 2019-08-22 | ゼルダ セラピューティクス オペレーションズ ピーティーワイ リミテッド | Cannabis composition |
| SG11201900501RA (en) | 2016-08-03 | 2019-02-27 | Zelda Therapeutics Operations Pty Ltd | Cannabis composition |
-
2017
- 2017-08-03 KR KR1020217002290A patent/KR20210013645A/en not_active IP Right Cessation
- 2017-08-03 MX MX2019001285A patent/MX2019001285A/en unknown
- 2017-08-03 AU AU2017307643A patent/AU2017307643B2/en active Active
- 2017-08-03 IL IL264461A patent/IL264461B2/en unknown
- 2017-08-03 JP JP2019505171A patent/JP2019523283A/en active Pending
- 2017-08-03 WO PCT/AU2017/050814 patent/WO2018023163A1/en unknown
- 2017-08-03 CA CA3031810A patent/CA3031810A1/en active Pending
- 2017-08-03 BR BR112019001852-2A patent/BR112019001852A2/en not_active Application Discontinuation
- 2017-08-03 CN CN201780060688.4A patent/CN109843287A/en active Pending
- 2017-08-03 EP EP17836097.0A patent/EP3493798A4/en active Pending
- 2017-08-03 IL IL296008A patent/IL296008B2/en unknown
- 2017-08-03 SG SG11201900665VA patent/SG11201900665VA/en unknown
- 2017-08-03 PE PE2019000330A patent/PE20200726A1/en unknown
- 2017-08-03 KR KR1020197005589A patent/KR20190035791A/en not_active Application Discontinuation
-
2018
- 2018-07-03 AU AU2018100923A patent/AU2018100923C4/en active Active
-
2019
- 2019-01-31 CL CL2019000270A patent/CL2019000270A1/en unknown
- 2019-02-01 CO CONC2019/0001044A patent/CO2019001044A2/en unknown
- 2019-10-23 AU AU2019253841A patent/AU2019253841B2/en active Active
-
2021
- 2021-10-01 AU AU2021240297A patent/AU2021240297B2/en active Active
-
2022
- 2022-07-14 US US17/865,024 patent/US11779562B2/en active Active
-
2023
- 2023-09-01 US US18/460,012 patent/US20230414559A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2021240297B2 (en) | 2023-08-24 |
| AU2019253841A1 (en) | 2019-11-14 |
| IL296008A (en) | 2022-10-01 |
| IL264461B1 (en) | 2024-05-01 |
| EP3493798A1 (en) | 2019-06-12 |
| IL264461B2 (en) | 2024-09-01 |
| EP3493798A4 (en) | 2020-05-06 |
| KR20210013645A (en) | 2021-02-04 |
| IL264461A (en) | 2019-02-28 |
| US20230414559A1 (en) | 2023-12-28 |
| AU2021240297A1 (en) | 2021-10-28 |
| AU2019253841B2 (en) | 2021-07-01 |
| KR20190035791A (en) | 2019-04-03 |
| AU2018100923C4 (en) | 2019-10-31 |
| BR112019001852A2 (en) | 2019-05-07 |
| JP2019523283A (en) | 2019-08-22 |
| PE20200726A1 (en) | 2020-07-21 |
| US11779562B2 (en) | 2023-10-10 |
| AU2018100923A4 (en) | 2018-08-09 |
| CN109843287A (en) | 2019-06-04 |
| AU2017307643B2 (en) | 2019-07-25 |
| CA3031810A1 (en) | 2018-02-08 |
| AU2017307643A1 (en) | 2018-07-05 |
| AU2018100923B4 (en) | 2018-09-27 |
| CO2019001044A2 (en) | 2019-04-30 |
| IL296008B2 (en) | 2024-09-01 |
| WO2018023163A1 (en) | 2018-02-08 |
| MX2019001285A (en) | 2019-06-13 |
| IL296008B1 (en) | 2024-05-01 |
| CL2019000270A1 (en) | 2019-10-04 |
| US20220347155A1 (en) | 2022-11-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201900596XA (en) | Cannabis composition | |
| SG11201900665VA (en) | Cannabis composition | |
| SG11201900501RA (en) | Cannabis composition | |
| SG11201907427YA (en) | Engineered transferrin receptor binding polypeptides | |
| SG11201806322QA (en) | Maytansinoid derivatives, conjugates thereof, and methods of use | |
| SG11201903359RA (en) | Bispecific antibody against bcma and cd3 and an immunological drug for combined use in treating multiple myeloma | |
| SG11201804098TA (en) | Purinones as ubiquitin-specific protease 1 inhibitors | |
| SG11201906885TA (en) | Methods for the administration of certain vmat2 inhibitors | |
| SG11201804118VA (en) | Compositions comprising bacterial strains | |
| SG11201804211YA (en) | Compositions comprising bacterial strains | |
| SG11201804368QA (en) | Storage assembly for prosthetic valve | |
| SG11201907435PA (en) | Combinations of a 4-pyrimidinesulfamide derivative with active ingredients for the treatment of endothelin related diseases | |
| SG11201900554YA (en) | Spiro-lactam nmda modulators and methods of using same | |
| SG11201810420YA (en) | Antibodies to alpha-synuclein and uses thereof | |
| SG11201806544XA (en) | Compounds and methods of treating rna-mediated diseases | |
| SG11201900558RA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
| SG11201908092RA (en) | Anti-tigit antigen-binding proteins and methods of use thereof | |
| SG11201909561RA (en) | Octree-based convolutional neural network | |
| SG11201900546UA (en) | Spiro-lactam and bis-spiro-lactam nmda receptor modulators and uses thereof | |
| SG11201900551WA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
| SG11201900845YA (en) | Uses of il-13 antagonists for treating atopic dermatitis | |
| SG11201902949PA (en) | Pharmaceutical compositions and methods of treating cardiovascular diseases | |
| SG11201804589TA (en) | Piperidinone formyl peptide 2 receptor and formyl peptide 1 receptor agonists | |
| SG11202000333UA (en) | Bicyclic ketone compounds and methods of use thereof | |
| SG11201809882XA (en) | Pharmaceutical combinations for treating cancer |